Comprehensive Inpatient Clinical Pharmacy and Pharmacotherapy Study Notes

Cellulitis and Rule-Out Meningitis Antimicrobial Stewardship

  • Meningitis Evaluation and Antimicrobial De-escalation:

    • When clinical suspicion for active meningitis is low, patients initiated on empiric intravenous (IV) antimicrobial therapy can be safely de-escalated to oral (PO) agents targeted for localized cellulitis once diagnostic procedures (such as lumbar puncture) and formal consultations are finalized.
  • Cefepime Dosing Timeline:

    • Initiation Date: Saturday, September 21st21\text{st}.
    • Duration and Completion: Completed on Day 77 (Thursday, September 26th26\text{th}) for empiric broad-spectrum Gram-negative coverage.
  • Vancomycin Dosing Timeline and Coverage:

    • Initiation Date: Tuesday, September 24th24\text{th} (initiated due to new-onset fever outbreak and clinical decline while on steroids).
    • Day 11 of Vancomycin defined as September 24th24\text{th}.
    • Methicillin-Resistant Staphylococcus aureus (MRSA) Course: Prescribed for a total duration of 7 days7\text{ days}, targeting completion on September 30th30\text{th} or October 1st1\text{st} (with September 28th28\text{th} representing Day 55).
  • Concomitant Steroid Therapy:

    • Patient received a multi-day course of systemic corticosteroids indicated for an acute exacerbation of underlying Chronic Obstructive Pulmonary Disease (COPD).
  • Oral Antibiotic Step-Down Options:

    • Doxycycline: Prescribed at 100 mg100\,\text{mg} orally every 12 hours12\,\text{hours} (q12hq12\text{h}). On Day 55, the morning administration consisted of 5 tablets5\text{ tablets} of 100 mg100\,\text{mg}, with 5 additional doses5\text{ additional doses} required upon discharge to complete the standard 7-day7\text{-day} course.
    • Levofloxacin: Initiated recently with a monitored baseline QTc interval of 463 ms463\,\text{ms}. If the clinical decision is made to complete a full 10-day10\text{-day} fluoroquinolone course, an additional 2 to 2.5 days2\text{ to }2.5\text{ days} (5 doses5\text{ doses}) of oral levofloxacin may be prescribed; otherwise, it may be safely discontinued if the 7-day7\text{-day} course is deemed sufficient.

Decompensated Alcohol-Associated Cirrhosis, Ascites, and SBP Management

  • Clinical Presentation and SBP Rule-Out:

    • Presentation: Patient presented with acute abdominal pain lasting several days secondary to severe ascites in the setting of decompensated alcohol-associated cirrhosis. The patient routinely undergoes therapeutic paracentesis every 2 weeks2\text{ weeks}.
    • Spontaneous Bacterial Peritonitis (SBP) Assessment: SBP occurs secondary to bacterial translocation from ascitic fluid accumulation. SBP was clinically ruled out based on the absence of systemic inflammatory response syndrome (SIRS) or sepsis criteria (normal white blood cell count, afebrile status, and normal baseline blood pressure without severe hypotension).
    • Empiric Antibiotic Exposure: Received a single empiric dose of IV ceftriaxone in the Emergency Department (ED).
    • Diagnostic Paracentesis Sample Loss: The initial ascitic fluid tube opened in transit to the laboratory, rendering the sample lost and unusable. Repeat paracentesis performed after antibiotic administration carries a high likelihood of false-negative culture results.
  • Therapeutic Paracentesis and Albumin Administration Guidelines:

    • Bedside ultrasound must confirm a safe, adequate fluid pocket prior to inserting a paracentesis needle to mitigate procedural risks.
    • Albumin Dosing Protocol: According to clinical practice guidelines, when paracentesis removes 5 L5\,\text{L} or more of ascitic fluid, IV albumin must be co-administered to prevent post-paracentesis circulatory dysfunction and acute kidney injury (AKI).
    • Albumin Dosage: 6 to 8 g6\text{ to }8\,\text{g} of IV albumin per liter (g/L\text{g/L}) of ascitic fluid removed beyond the 5 L5\,\text{L} threshold.
  • Diuretic Therapy and Electrolyte Dynamics:

    • Theoretical Ratio: The classical theoretical ratio for managing cirrhotic ascites is Spironolactone 100 mg100\,\text{mg} to Furosemide 40 mg40\,\text{mg} (100 mg:40 mg100\,\text{mg} : 40\,\text{mg}), designed to maintain potassium balance.
    • Clinical Realities: Clinical practice frequently deviates from the 100 mg:40 mg100\,\text{mg} : 40\,\text{mg} ratio due to variations in renal function, baseline serum potassium, and systemic blood pressure.
    • Current Patient Regimen: Spironolactone (Aldactone) 25 mg25\,\text{mg} daily (home dose) with no loop diuretic (Lasix).
    • Laboratory Trends: Serum potassium recovered from 2.5 mEq/L2.5\,\text{mEq/L} yesterday to 4.0 mEq/L4.0\,\text{mEq/L} today. Serum creatinine increased by 0.2 mg/dL0.2\,\text{mg/dL} over 24 hours24\,\text{hours}, indicating declining renal function.
    • Hemodynamic Constraints: Diuretic uptitration is restricted by soft systemic blood pressure. Overly aggressive diuresis reduces renal perfusion, precipitates AKI, decreases renal excretion of potassium, and disrupts diuretic efficacy, forcing fluid resuscitation.
  • Esophageal Varices and Beta-Blocker Indications:

    • Endoscopic Findings: Esophagogastroduodenoscopy (EGD) performed in August revealed Grade 33 esophageal varices that underwent successful endoscopic band ligation (EBL). Rubber bands typically slough off spontaneously within 5 to 7 days5\text{ to }7\text{ days}.
    • Primary vs. Secondary Prophylaxis: Non-selective beta-blockers (NSBBs) are not indicated for primary prophylaxis in a patient whose varices have been banded and who has no history of acute esophageal variceal hemorrhage. NSBBs are strictly indicated for secondary prophylaxis following an established variceal bleed.

Acute Limb Ischemia and Nontuberculous Mycobacterial Infection Management

  • Acute Limb Ischemia Protocol:

    • Presentation: Thrombotic occlusion in the arterial vasculature leading to acute limb ischemia.
    • Anticoagulation Purpose: Therapeutic unfractionated heparin infusion is initiated to prevent further clot propagation and progression; heparin does not lyse existing established clots.
    • Pre-operative Management: Patient designated NPO (nothing by mouth) for Right Renal Artery (RRA) vascular surgery; daily basal insulin (Lantus) dose was reduced.
  • Nontuberculous Mycobacterial (NTM) Diagnostic Workup:

    • Sputum Sample Failure: Speech-Language Pathologists (SLP) determined the patient was unable to produce sufficient sputum volume; bedside bronchoscopy scheduled for sample retrieval.
    • Acid-Fast Bacilli (AFB) Testing: Diagnostic AFB stain and culture take extended periods due to slow-growing mycobacterial organisms.
  • NTM Pharmacotherapy Principles:

    • Treatment Duration: Requires long-term antimicrobial therapy consisting of at least 6 months6\text{ months} of IV antibiotics, extending up to 1 year1\text{ year} total.
    • Combination Regimen: Requires multi-drug combination therapy (e.g., Azithromycin or Clarithromycin + Rifampin + Aminoglycoside) tailored to specific species resistance profiles.

Transplant Infectious Disease and Immunosuppressive Drug Monitoring

  • Patient Presentation (Patient RA):

    • Demographics: 63-year-old63\text{-year-old} male with End-Stage Renal Disease (ESRD), resolving Type 1 Diabetes Mellitus, and a history of dual Pancreas-Liver transplantation on maintenance immunosuppression.
    • Admission Reason: Transferred from an outside facility presenting with fever, right toe cellulitis, and concern for sepsis (meningitis ruled out).
  • Antimicrobial Management:

    • Regimen: Empiric Zosyn (piperacillin/tazobactam), Vancomycin, Acyclovir prophylaxis, and IV Ampicillin.
    • De-escalation: Discontinue Ampicillin once Listeria monocytogenes central nervous system infection is ruled out.
  • Cytomegalovirus (CMV) Prophylaxis and Reactivation:

    • Risk Profile: Donor positive / Recipient negative (D+/R−D+/R-) status represents high risk for primary CMV infection.
    • Prophylaxis History: Valganciclovir 900 mg900\,\text{mg} orally twice daily (BIDBID) maintained for 1 year1\text{ year} post-transplant (until March 20242024) and stopped following negative CMV PCR assays.
    • Equivocal Result Management: Current CMV PCR returned equivocal. Treatment course requires a minimum of 2 weeks2\text{ weeks} of full-dose antiviral therapy until repeat CMV PCR yields negative results.
  • Immunosuppressive Therapeutic Drug Monitoring (TDM):

    • Regimen: Tacrolimus, Mycophenolate Mofetil, and Prednisone.
    • Tacrolimus Target Level: Goal trough range is 5 to 7 ng/mL5\text{ to }7\,\text{ng/mL}.
    • Laboratory Trends: Serum level was 9.9 ng/mL9.9\,\text{ng/mL} yesterday and 8.6 ng/mL8.6\,\text{ng/mL} today (drawn early at 05:3005:30; current dosing schedule is 2 mg2\,\text{mg} morning / 1.5 mg1.5\,\text{mg} afternoon).
    • Infection Management: During acute severe systemic infections, transplant nephrology may temporarily reduce the Mycophenolate Mofetil dosage while preserving Tacrolimus target levels to restore leukocyte immune function.

Intracranial Hemorrhage and Clinical Pharmacokinetic Workflow

  • Patient Presentation (Jack Davis):

    • Diagnosis: Admitted with intracranial hemorrhage scheduled for surgical intervention; total IV antibiotic duration anticipated at 2 weeks2\text{ weeks}.
    • Glycemic Control: Blood glucose levels consistently exceed 200 mg/dL200\,\text{mg/dL}, indicating a need for basal insulin (Lantus) initiation.
  • Epic Flowsheet Pharmacokinetic Documentation Workflow:

    • Step 1: Access the Pharmacy Antibiotics Data Flowsheet in the patient chart.
    • Step 2: Document daily dosing parameters and infusion schedules (e.g., 11:3011:30 maintenance bag timing) in the top section of the flowsheet.
    • Step 3: Enter drawn serum vancomycin trough concentrations and pharmacokinetic assessments into the lower section of the flowsheet upon lab return.
    • Step 4: Click FILE inside the flowsheet prior to navigating away or opening notes to save data to the Epic database.
    • Step 5: Navigate to Notes -> New Note -> Title: Progress Note -> Cosigner: Assigned Preceptor.
    • Step 6: Type the SmartPhrase .bankfollowup or .bank to automatically pull all saved flowsheet values into the formal progress note.

Dog Bite Management, Tetanus, and Rabies Prophylaxis Protocols

  • Antimicrobial Management:

    • Pathogens: Dog bite wounds expose patients to Pasteurella multocida, oral anaerobes, and skin flora.
    • Duration: Antibiotic duration ranges from 5 to 7 days5\text{ to }7\text{ days} (5 days5\text{ days} if clinical response and wound healing are rapid).
  • Tetanus Prophylaxis Guidelines:

    • Routine Booster: Every 10 years10\text{ years} for clean, minor wounds.
    • High-Risk / Dirty / Puncture / Animal Bite Wounds: Administer a tetanus booster if the last dose was received more than 5 years5\text{ years} ago.
  • Rabies Post-Exposure Prophylaxis (PEP) Guidelines:

    • Indications: Required for bites from stray animals, wild animals (bats, raccoons, squirrels), or domestic animals with unverified vaccination status. Unnecessary if the domestic animal is known and confirmed vaccinated.
    • Vaccine Schedule: 4 doses4\text{ doses} total, administered intramuscularly on Days 00, 33, 77, and 1414.
    • Rabies Immune Globulin (HRIG): Administered on Day 00 alongside the initial vaccine dose to provide immediate passive immunity. The full calculated HRIG dose should be infiltrated locally into and around the bite wound site if anatomically feasible.
    • Outpatient Access Constraints: Retail pharmacies generally stock pre-exposure prophylaxis only; post-exposure prophylaxis must be coordinated directly through Local Health Departments (LHD).

Patient-Controlled Analgesia (PCA) Mechanics and Dosing Principles

  • PCA Line Plumbing:

    • Carrier Fluids: Low-volume PCA drug delivers (e.g., 1.2 mL1.2\,\text{mL}) will stall inside IV tubing. A continuous carrier line flush running at 10 mL/h10\,\text{mL/h} is required to flush the drug into systemic circulation.
  • PCA Parameter Setup:

    • Opioid Naive vs. Tolerant: Continuous basal rate infusions are contraindicated in opioid-naive patients due to high risks of fatal respiratory depression.
    • Basal Rate Conversion: For opioid-tolerant patients (e.g., chronic oral MS Contin 30 mg30\,\text{mg}), convert approximately 10%10\% of the total daily MME into a continuous basal hourly infusion rate.
    • Demand Dose: Specific bolus dose delivered upon button push (e.g., Hydromorphone 0.2 mg0.2\,\text{mg}).
    • Lockout Interval: Minimum allowable time delay between doses (e.g., 15 minutes15\,\text{minutes}).
    • Hourly Maximum Calculation:Hourly Maximum=(60 minLockout Interval (min))×Demand Dose+Basal Rate\text{Hourly Maximum} = \left( \frac{60\,\text{min}}{\text{Lockout Interval (min)}} \right) \times \text{Demand Dose} + \text{Basal Rate}Example: A 0.2 mg0.2\,\text{mg} demand dose with a 15-minute15\text{-minute} lockout (4 doses/hour4\text{ doses/hour}) and 0 mg/h0\,\text{mg/h} basal rate yields an hourly dose limit of 0.8 mg/h0.8\,\text{mg/h}.
  • Epic Pain Monitoring Audit:

    • Tracks total patient attempts versus injected doses (e.g., 27 doses27\text{ doses} delivered from 45 attempts45\text{ attempts}, totaling 5.4 mg5.4\,\text{mg} infused over 12 hours12\text{ hours} at 0.2 mg/dose0.2\,\text{mg/dose}). Reset pump counters every 12 hours12\text{ hours} (07:0007:00 and 19:0019:00).

Clinical Pharmacy Practice, Acute Care Transition, and Pulmonary Embolism Guidelines

  • Inpatient Clinical Focus:

    • Prioritize acute inpatient problems driving hospitalization over chronic outpatient disease management.
    • Identify transition-of-care opportunities: convert IV antibiotics to PO equivalents, discontinue unneeded heparin drips, and streamline medication regimens for discharge.
  • Interprofessional Rounds Communication:

    • Deliver concise, direct recommendations to the medical team. Express clinical judgments assertively during multidisciplinary rounds.
  • Pulmonary Embolism (PE) Guidelines:

    • Modern PE risk stratification replaces simplified massive vs. submassive categories with clinical hemodynamic parameters, right ventricular strain metrics, and troponin/BNP elevations.
    • Anticoagulation selection involves evaluating direct oral anticoagulants (DOACs), low-molecular-weight heparin (LMWH), and unfractionated heparin (UFH) based on acute renal clearance and thrombolytic eligibility.